IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 11, May 2026
Impact Factor: 8.2

# The Impact of Formulation Variables on the Therapeutic Efficacy of Liposomal System; A Review

**Dr. Chavan D. K., Mr. Wanve Vishwajeet Sakharam**
**Mr. Pathan Zahir Khan Ilyas Khan, Mr. Ughade Gokul Tukaram**
Aditya Pharmacy College, Beed

**Abstract:** *Liposomal drug delivery systems have emerged as an advanced approach for targeted and controlled drug delivery. Liposomes are spherical vesicles composed of phospholipid bilayers capable of encapsulating both hydrophilic and lipophilic drugs. The present study focuses on the preparation and evaluation of liposomal drug delivery system.*

*Liposomes were prepared using the thin film hydration method, which is widely accepted due to its simplicity and efficiency. In this method, phospholipids and cholesterol were dissolved in an organic solvent and a thin lipid film was formed by solvent evaporation. The film was then hydrated with an aqueous phase containing the drug to produce liposomes.*

*The prepared liposomes were evaluated for various parameters such as particle size, entrapment efficiency, drug release, and stability. Particle size plays a significant role in drug distribution and targeting efficiency. Entrapment efficiency determines the amount of drug successfully incorporated into the liposomes.*

*In-vitro drug release studies were carried out to assess the release pattern of the drug from the formulation. Stability studies were also conducted to determine the shelf-life and robustness of the formulation.*

*The results indicated that the prepared liposomes exhibited satisfactory entrapment efficiency and controlled drug release profile. The liposomal formulation showed improved bioavailability and reduced toxicity compared to conventional dosage forms.*

*The study concludes that liposomal drug delivery system is a promising and effective approach for enhancing therapeutic efficacy. This system has great potential in the field of modern pharmaceutics for targeted and sustained drug delivery applications.*

*pects.*

**Keywords:** Liposomal Drug Delivery System, Formulation Variables, Therapeutic Efficacy, Phospholipids, Cholesterol, Thin Film Hydration Method, Entrapment Efficiency, Drug Release, Particle Size, Stability, Targeted Drug Delivery, Nanomedicine.

## I. INTRODUCTION

The ultimate goal of therapeutics is to deliver a precise amount of a medicinal agent to a specific pathological site at the optimal rate. However, conventional drug delivery systems, such as standard oral tablets, intravenous solutions, and immediate-release injections, often fall short of this ideal.[1]

They frequently suffer from significant limitations, including poor aqueous solubility, low bioavailability, rapid enzymatic or chemical degradation within the biological environment, and a lack of target specificity. This systemic distribution means that high doses are required to achieve therapeutic efficacy at the target site, which inadvertently exposes healthy tissues to toxic drug levels, leading to severe adverse side effects. To overcome these structural and

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

pharmacological drawbacks, nanomedicine has pioneered the development of novel drug delivery systems. Among these nanotechnology-based platforms, the liposomal drug delivery system stands out as one of the most clinically successful and promising approaches. [2]

First described in 1965 by British haematologist Alec D. Bangham, liposomes are microscopic, spherical vesicles composed of one or more concentric lipid bilayers enclosing an internal aqueous core. The structural building blocks of these vesicles are phospholipids, which possess an amphiphilic nature, containing a hydrophilic head group and a hydrophobic hydrocarbon tail. When exposed to an aqueous environment, these molecules spontaneously organize into tail-to-tail configurations to shield their hydrophobic regions from water, effectively creating a closed membrane barrier. This unique dual-compartment architecture grants liposomes unparalleled versatility in pharmaceutical applications because hydrophilic drugs can be physically trapped within the central aqueous core, while lipophilic drugs are intercalated directly into the hydrophobic interior of the lipid bilayer. Because they are synthesized primarily from natural phospholipids, such as egg or soybean phosphatidylcholine, liposomes are fundamentally biocompatible, biodegradable, non- immunogenic, and non-toxic, making them ideal vehicles for therapeutic use. [3]

Liposomes are classified based on their structural architecture, specifically their physical size and the number of lipid layers, which determines their lamellarity. Small Uniflagellar Vesicles range from 20 to 100 nm with a single bilayer, whereas Large Uniflagellar Vesicles occupy the range from 100 to 1000 nm with a single bilayer, and Multilamellar Vesicles exceed 500 nm while consisting of multiple, onion-like concentric lipid bilayers. Various techniques are deployed for their Project Work, with the Thin-Film Hydration Method being the most widely utilized laboratory technique due to its simplicity, reproducibility, and effectiveness. In this method, the lipids and lipophilic components are completely dissolved in an organic solvent to ensure molecular mixing. The solvent is subsequently evaporated under reduced pressure to form a uniform, thin lipid film on the walls of a flask, which is then physically hydrated with an aqueous buffer containing the hydrophilic drug, forcing the lipid sheets to swell, detach, and self-assemble into microscopic vesicles. [4]

The therapeutic journey of a liposome, from the point of administration to its intracellular uptake, is not merely driven by the drug it carries, but is profoundly dictated by its chemical formulation variables. In modern nanomedicine, a liposome is viewed as an engineered micro mechanism where minor adjustments in the composition translate to radical shifts in clinical performance. The length and degree of saturation of the phospholipid hydrocarbon chains dictate the phase transition temperature, meaning that choosing a lipid that remains rigid at body temperature prevents premature drug dumping in circulation. Cholesterol concentration acts as another critical variable by serving as a fluidity buffer; it inserts into the gaps between phospholipid molecules, decreasing membrane permeability, preventing leaks, and providing the mechanical stiffness required to withstand systemic blood shear stress. [5]

Furthermore, the inclusion of charged lipids modifies the vesicle's surface charge, which directly prevents particle clumping through electrostatic repulsion, while optimizing size remains vital for exploiting the enhanced permeability and retention effect to allow liposomes to pass through the leaky blood vessels of tumour tissues while avoiding clearance by the liver and spleen. By carefully tuning these variables, researchers can protect sensitive molecules from biological degradation, maintain a controlled and sustained drug release pattern, increase the circulation half-life, and significantly improve the therapeutic index of a drug by maximizing efficacy while minimizing systemic toxicity.[6]

To ensure the clinical viability and quality of any nanocarrier system, rigorous characterization is required. Evaluation parameters such as particle size distribution, polydispersity index, entrapment efficiency, in-vitro drug release profiles, and long-term stability under varying storage temperatures are crucial benchmarks of performance. While liposomal formulations have already demonstrated remarkable therapeutic superiority over conventional dosage forms in treating cancers, severe systemic infections, and chronic inflammatory disorders, the seeking of an optimized formulation remains an ongoing pharmaceutical challenge. [7]

In the present study, an attempt has been made to prepare and evaluate a liposomal drug delivery system using the thin-film hydration method. By Systematically altering critical formulation variables, specifically the ratio of structural phospholipids to stabilizing cholesterol, this project aims to evaluate how these modifications influence critical

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 11, May 2026
Impact Factor: 8.2

parameters like drug entrapment and sustained release kinetics. Ultimately, this study highlights the potential of precisely engineered liposomes as highly effective, stable, and controllable carrier systems for advanced drug delivery applications. [8]

In addition to reshaping systemic transport dynamics and circulation half-life, the precise manipulation of formulation variables plays a definitive role in the final intracellular fate of the encapsulated payload. Once a liposome successfully navigates the complex vascular network and accumulates at the target pathological site, its therapeutic efficiency becomes entirely dependent on its ability to transfer its molecular cargo into the target cells. The nature of the structural phospholipids selected during the initial preparation step dictates how the vesicle membrane interacts with the hydrophobic domains of cellular membranes. Formulations with optimized surface properties can exploit natural cellular uptake pathways, such as receptor-mediated endocytosis or direct membrane fusion, which bypasses the standard cellular degradation machinery. Without this precise macromolecular design, internalized liposomes are frequently shunted into the harsh environment of lysosomes, where aggressive hydrolytic enzymes and low pH levels can destroy sensitive therapeutic compounds before they ever reach their intended intracellular targets, such as the nucleus or the cytosol. Furthermore, the mechanical and thermodynamic properties established by the lipid-to-cholesterol ratio directly govern the scalability and industrial reproducibility of the manufacturing process. From a practical pharmaceutical development perspective, a liposomal formulation must not only perform optimally in a controlled laboratory setting but must also remain structurally resilient during standard processing stressors, such as high-pressure homogenization, micro fluidization, and sterile filtration. Bilayers that lack the structural buffering effect of cholesterol are highly susceptible to mechanical shear degradation, which can lead to catastrophic vesicle rupture and massive drug leakage during large-scale manufacturing runs. Similarly, the long-term phase behaviour of the lipid film during industrial storage determines whether the formulation will maintain its uniform nanometric size or undergo premature fusion and sedimentation over time. By carefully establishing the thermodynamic boundaries of the lipid matrix, researchers can ensure that the nanocarriers preserve their uniform particle size distribution and high entrapment efficiency under standard regulatory shelf-life conditions. [9]

Ultimately, these interconnected chemical, biological, and mechanical factors emphasize that the development of an optimized liposomal system requires a careful balance between multiple competing variables. Maximizing drug entrapment, extending systemic circulation, facilitating efficient cellular Internalization, and ensuring robust industrial stability are often conflicting goals that cannot be achieved through a single, unvaried composition. This reality highlights the importance of systematic optimization studies that map the precise boundaries of lipid-to-cholesterol ratios. Through rigorous experimental evaluation of these critical formulation components, it becomes possible to transition liposomes from simple laboratory phenomena into highly reliable, reproducible, and clinically successful therapeutic platforms capable of addressing the complex challenges of modern targeted Nano medicine. [10]

Therefore, the systematic preparation and rigorous characterization of these Nano carriers remain vital for translating laboratory success into reproducible clinical outcomes. By utilizing the thin- film hydration method to carefully map and evaluate the experimental boundaries of lipid-to-cholesterol ratios, this project bridges the gap between fundamental lipid chemistry and optimized Nano-manufacturing. The subsequent evaluation of critical benchmarks—such as uniform particle size distribution, high entrapment efficiency, controlled biphasic drug release, and long-term storage stability— serves to validate the structural integrity and performance of the engineered system. Ultimately, the insights gained from this study reaffirm that precisely optimized liposomal formulations hold profound potential as highly controllable, stable, and effective platforms, paving the way for safer and more successful targeted therapeutic interventions.

## II. LITERATURE OF REVIEW

Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine. 2012 Dec 30:49-60.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Advanced Drug Delivery Reviews. 1999 Nov 10;40(1-2):75-87.
Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. Journal of Liposome Research. 2012 Sep 1;22(3):177-92.
Gonzalez-Rodriguez ML, Barros LB, Palma J, González-Rodríguez PL, Rabasco AM. Application of statistical experimental design to study the formulation variables influencing the coating process of lidocaine liposomes. International Journal of Pharmaceutics. 2007 Jun 7;337(1-2):336-45.
Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. Journal of Controlled Release. 2009 Oct 1;139(1):73-80.
Ait-Oudhia S, Mager DE, Straubinger RM. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics. 2014 Mar 18;6(1):137-74.
Maritim S, Boulas P, Lin Y. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes. International Journal of Pharmaceutics. 2021 Jan 5;592:120051.
Chountoulesi M, Naziris N, Pippa N, Demetzos C. The significance of drug-to-lipid ratio to the development of optimized liposomal formulation. Journal of Liposome Research. 2018 Jul 3;28(3):249-58.
Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. International Scholarly Research Notices. 2012;2012(1):738432.
He H, Yuan D, Wu Y, Cao Y. Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs. Pharmaceutics. 2019 Mar 7;11(3):110.

**1. Introduction and Foundations of Liposomal Nanocarriers**

1. Barenholz Y. et al Relevancy of drug loading to liposomal formulation therapeutic efficacy. Journal of Liposome Research. 2003 Jan The clinical utility of conventional chemotherapeutics is severely restricted by systemic toxicity and poor target tissue accumulation. This fundamental oncological challenge is effectively bypassed by liposomes—microscopic vesicles composed of an aqueous core enclosed by phospholipid bilayers

**2. Structural Dimensions and Pharmacokinetic Variations**

The design of clinically viable liposomal nanocarriers for oncology relies heavily on understanding how a vesicle's physical dimensions dictate its behavior inside a living organism. As established by Nagayasu, Uchiyama, and Kiwada (1999), early attempts to encapsulate chemotherapy drugs into liposomes succeeded in lowering overall toxicity, but they frequently failed to improve antitumor performance. This historical limitation occurred because researchers lacked precise data regarding how these carriers accumulate inside solid tumors in relation to their foundational pharmacokinetics and physicochemical properties.

According to Nagayasu et al. (1999), the ultimate therapeutic success of these systems depends on a delicate sequence of biological events:

• Maintaining high concentrations and residence time in the bloodstream.
• Extravasating through leaky vessel walls into the tumor's interstitial space via the Enhanced Permeability and Retention (EPR) effect.
• Staying trapped within the malignant tissue.
• Releasing the drug at the optimal rate without leaking prematurely into systemic circulation.

Among all formulation parameters, the physical size of the liposome has emerged as a critical structural variable that directly regulates blood circulation longevity, controls tissue penetration, and alters downstream therapeutic activity. Exploring how nanometric vesicle size influences the bridge between pharmacokinetic behavior and localized tumor targeting is essential for engineering next-generation,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

high-performance liposomal anti-cancer drugs.

**3. Managing Host and Carrier Variability**

The clinical application of nanomedicine relies heavily on strategies designed to maximize the therapeutic index of potent active molecules while minimizing their systemic side effects. As explored by Song, Wu, Yoshino, and Zamboni (2012), liposomes represent one of the most advanced technology platforms capable of directing active drugs precisely to their intended site of action. Historically, however, the intravenous administration of these carriers has been bottlenecked by the rapid clearance of liposomal drugs from the bloodstream—a critical flaw because circulation longevity directly governs drug exposure at the target pathological tissue.

Compounding this challenge, Song et al. (2012) emphasize that the clinical utility of liposomal agents is frequently complicated by significant intra- and inter-individual variability in their pharmacokinetics (PK) and pharmacodynamics (PD). Optimizing these formulations therefore requires a thorough understanding of the interconnected factors driving this variability, which are broadly categorized into:

1. Liposome-associated features: Vesicle size, surface charge, and lipid density.
2. Host-associated physiological responses: Macrophage activity and immune clearance (Reticuloendothelial System interaction).
3. Treatment regimens: Dosage schedules and combination therapies.

Mapping how these distinct compositional, biological, and clinical variables interact to alter pharmacokinetic and pharmacodynamic outcomes is essential for minimizing patient variability and engineering more predictable therapies.

**4. Mechanisms and Thermodynamics of Drug Loading**

The therapeutic efficacy and clinical transition of liposomal drug delivery systems are fundamentally governed by the efficiency and mechanism of their drug loading processes. As detailed by Yechezkel Barenholz (2003), the quantitative relationship between the drug payload and the structural lipid matrix—commonly referred to as the drug-to-lipid ratio—serves as a primary benchmark for determining a formulation's ultimate therapeutic success. Historically, passive encapsulation techniques often resulted in low loading efficiency and a high fraction of unencapsulated drug, leading to premature leakage in systemic circulation and sub-therapeutic dosing at the target tissue.

To overcome these limitations, Barenholz (2003) highlights the critical relevance of active, or remote, drug loading methods driven by transmembrane gradients (such as ammonium sulfate or pH gradients). These chemical driving forces actively force amphipathic weak bases or acids to accumulate at exceptionally high concentrations inside the liposomal aqueous core. This precise control over the loading environment not only dramatically elevates encapsulation efficiency but also dictates the physical state of the drug inside the vesicle, stabilizes the carrier against premature blood clearance, and patterns its subsequent release kinetics at the pathological site.

Passive Loading Active (Remote) Loading

[ Low Efficiency ] [ High Efficiency via Gradients ] Drug leaks out Ionized

drug trapped in core

easily in vivo Stable, controlled release

**5. Predictive In Silico Modelling of Loading Efficiency**

To transition this process from empirical trial-and-error to a predictive science, Zucker, Marcus, Barinholtz, and Goldblum (2009) applied computational data-mining algorithms to fifteen years of experimental loading data across various therapeutics. While transmembrane gradients represent a monumental breakthrough that enabled the regulatory approval of nanomedicines like Doxil™, a predictive understanding of how loading conditions interact with a molecule's distinct chemical structure had historically been missing.

The quantitative model developed by Zucker et al. (2009) successfully maps the multifactorial relationships between a drug's physicochemical properties (such as pK_a , aqueous solubility, and molecular weight) and specific operational

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

constraints. This intelligent framework allows researchers to strategically select optimal candidate molecules, engineer compatible pro-drugs, and fine-tune loading parameters to accelerate the development of high-performance liposomal formulations without relying on exhaustive manual screenings.

**6. Multi-Parametric Lipid Engineering and Optimization**

6.1 Compositional Variables: Chain Length, Saturation, and Sterols

The rational design of clinically viable liposomal formulations depends heavily on a comprehensive understanding of how physical and chemical parameters alter critical performance benchmarks, including vesicle size, encapsulation efficiency, colloidal stability, and drug release kinetics. As detailed by Samuel Maritim, Pierre Boulas, and Yiqing Lin (2020), developing effective vehicles for newly discovered small molecules is frequently bottlenecked by poor aqueous solubility and low bioavailability.

Using BIIB093 (glipalamide)—a highly challenging, weakly acidic central nervous system drug with low solubility—as a model compound, Maritim et al. (2020) systematically mapped the boundaries of lipid engineering. Evaluating PEGylated liposomes synthesized via a dual combination of ethanol injection and calcium acetate-driven remote loading, they demonstrated the following critical formulation dependencies:

| Formulation Variable | Impact on Liposomal Properties |
|---|---|
| Increased Acyl Chain Length | Markedly enhances drug loading, encapsulation metrics, and membrane retention. |
| High Lipid Unsaturation | Lowers the phase transition temperature ( T_c ), triggering accelerated drug release rates. |
| Optimized Cholesterol Ratio | Acts as a powerful lever to increase membrane rigidity and lower the polydispersity index (PDI) without distorting vesicle size or zetapotential. |

Ultimately, this multi-parametric analysis highlights that systematically tailoring compositional and structural boundaries is a vital prerequisite for shifting liposomal manufacturing to a highly predictable, extended-release nanotechnology platform.

**6.2 Statistical Design of Experiments (DoE) in Formulation Science**

The development and optimization of advanced pharmaceutical dosage forms are heavily challenged by the vast number of interconnected variables that simultaneously influence vesicle stability and performance. As demonstrated by González-Rodríguez, Barros, Palma, González-Rodríguez, and Rabasco (2007), the traditional approach of altering one formulation factor at a time is incredibly complex, expensive, and time-consuming. To overcome this engineering bottleneck, González- Rodríguez et al. (2007) successfully applied Statistical Experimental Design (Design of Experiments - DoE) methodology—specifically a fractional factorial screening matrix—to rapidly evaluate and isolate the key variables governing the fabrication and biopolymer-coating process of lidocaine hydrochloride liposomes.

Their research underscores that the interplay between distinct formulation components (such as drug concentration and chitosan coating density) and technological processing parameters (such as stirring speeds, dripping rates, and aging time before coating) directly determines vital performance responses, including drug encapsulation efficiency (EE), coating efficiency (CE), and zeta potential. By utilizing a multi-factor experimental framework, researchers can map complex macromolecular interactions and systematically establish optimal operational levels, shifting liposomal design from trial-and-error experimentation to a streamlined, rational manufacturing science.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

**7. Quantitative Simulation and Future Clinical Horizons**

The clinical advancement of nanomedicine in oncology depends heavily on modulating the in vivo behaviour of cytotoxic agents to simultaneously maximize tumour drug deposition and shield healthy tissues from systemic toxicities. As reviewed by Ait-Oudhia, Mager, and Straubinger (2014), liposomes have achieved extensive clinical and regulatory success, exemplified by approved formulations such as Doxil®, Myocet®, and Marqibo®. By fundamentally altering the PK of encapsulated payloads, these biocompatible carriers prolong plasma circulation half-lives, reduce the metabolism of labile drugs, and exploit the EPR effect to selectively extravasate through leaky tumour blood vessels.

However, Ait-Oudhia et al. (2014) note that optimizing these multi-layered systems remains largely empirical due to a complex web of formulation variables, including lipid composition, membrane charge, PEGylation for steric stabilization, and surface ligands designed for active cellular targeting or triggered release. To bypass this empirical bottleneck, the integration of quantitative mathematical simulation and multi-scale PK/PD modelling has emerged as a transformative tool.

These computational approaches allow researchers to precisely map drug transport, vesicle disposition, interstitial release kinetics, and cellular uptake. Ultimately, utilizing advanced in silico modeling transforms liposomal design into a rational science, providing a quantitative framework to streamline formulation engineering and predict ideal conditions for combining nanoparticulate carriers with standard-of-care therapies.

Several studies have reported that liposomes enhance drug bioavailability and provide controlled as well as targeted drug delivery. According to various research findings, liposomal formulations reduce drug toxicity and improve pharmacokinetic properties. Researchers have demonstrated that liposomes can be effectively used in the treatment of cancer, infectious diseases, and inflammatory disorders.

Different methods have been developed for the preparation of liposomes, such as thin film hydration, reverse phase evaporation, and ethanol injection method.

Among these, the thin film hydration method is the most commonly used technique due to its simplicity, reproducibility, and ability to produce stable liposomal vesicles. Studies suggest that the composition of lipids and cholesterol plays a crucial role in determining the stability and efficiency of liposomes.

Evaluation of liposomal formulations is an important aspect in determining their effectiveness. Various parameters such as particle size, entrapment efficiency, drug release, and stability have been widely studied. It has been observed that smaller particle size leads to better absorption and enhanced drug delivery. High entrapment efficiency indicates better drug loading capacity, while controlled drug release ensures sustained therapeutic effect.

Recent advancements in liposomal drug delivery systems include the development of stealth liposomes, targeted liposomes, and ligand-mediated systems. These advanced formulations have shown improved circulation time and enhanced targeting ability. Overall, the literature suggests that liposomal drug delivery systems are a promising approach for improving drug delivery and therapeutic outcomes.

## III. AIM AND OBJECTIVES

Aim: The main aim of the present study is the impact of formulation variables on the Therapeutic efficacy of liposomal systems.

Objective:

1. To systematically evaluate the impact of preparation methods (such as thin-film hydration and solvent injection) on core physical liposomal properties, including vesicle size, lamellarity, and polydispersity index (PDI).
2. To investigate the relationship between lipid composition (acyl chain length, degree of saturation, and phase transition temperature,) and the structural integrity, storage stability, and membrane permeability of the vesicles.
3. To analyze the role of cholesterol concentration as a bilayer stabilizer and determine its specific influence on membrane rigidity, vesicle uniformity, and drug retention capacity.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

4. To compare the efficiency of passive versus active (remote) loading mechanisms, specifically evaluating how trans membrane pH or ion gradients influence the drug-to-lipid ratio and target encapsulation metrics.
5. To assess how surface charge (zeta potential) dictates the physical stability of the colloidal system, its interactions with biopolymer coatings (like chitosan), and its ability to prevent vesicle aggregation.
6. To evaluate the pharmacokinetic (PK) modifications driven by formulation variables, focusing on how vesicle configuration optimizes plasma circulation half-life and minimizes premature systemic drug leakage.
7. To explore the pharmacodynamics (PD) outcomes and targeting efficiency of tailored liposomes, analyzing how physical dimensions affect extravasation into pathological tissues via the Enhanced Permeability and Retention (EPR) effect.
8. To utilize advanced optimization tools, such as Statistical Design of Experiments (DoE) and computational in silico modeling, to map multi-factorial variables and establish a rational, predictable engineering framework for high-performance nanocarriers.

## III. METHOD AND MATERIALS

**Research Methodology:**

The primary objective of this experimental design is to systematically prepare, optimize, and evaluate liposomal systems containing a model drug. The research focuses on monitoring the structural, physical, and release changes that occur when modifying the lipid-to-cholesterol molar ratio from 10:0 down to 1:1 across six distinct batch formulations.

### 3.1 Materials and Reagents

The critical components utilized for the assembly, stabilization, and evaluation of the liposomal formulations are categorized below:

### 3.2 Liposome Formulation Design Matrix

To map the definitive impact of cholesterol concentration on structural efficiency, six experimental batches were developed with a fixed concentration of the model drug.

| Material Category | Specific Representative(s) | Functional Role in Assembly |
|---|---|---|
| Primary Lipid | Phosphatidylcholin e (PC) / DPPC /DSPC | Forms the structural backbone (lipid bilayer matrix). |
| Sterols | Cholesterol (CHOL) | Modulates membrane rigidity, fluidity, and permeability. |
| Charged Lipids | Stearyl amine (+)/Diacetyl phosphate (-) | Instils surface charge (Zeta Potential) to prevent vesicle clumping. |
| Hydration Medium | Phosphate Buffered Saline (PBS, pH 7.4) | Creates the aqueous core environment; mimics physiological pH. |
| Organic Solvent | Chloroform / Methanol / Ethanol | Dissolves solid lipid profiles to guarantee a homogenous molecular mix. |

### 3.3 Experimental Unit Operations (Step-by-Step Preparation)

[ lipid + cholesterol + drug ]>> Dissolve in Organic Solvent >>> Rotary Evaporation (Thin Film Formed)
|
[Final Liposomal Suspension ] << Characterization & Testing << Hydration with
PBS (pH 7.4)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

Step 1: Organic Dissolution and Molecular Blending

For each designated batch the specified quantities of primary phospholipid, cholesterol, and the model drug are weighed accurately. The materials are completely dissolved in a volatile organic solvent mixture (typically Chloroform and Methanol in a 2:1 v/v ratio) inside a clean, dry round-bottom flask. This step transitions the solid lipids into a perfectly homogenous, molecularly blended fluid phase.

Step 2: Thin-Film Desiccation (Rotary Evaporation)

The round-bottom flask is attached to a Rotary Evaporator. Distillation is carried out under reduced vacuum pressure at a controlled temperature elevated slightly above the specific lipid phase transition temperature As the volatile solvent completely evaporates, the amphiphilic molecules spontaneously arrange themselves into a uniform, smooth, semi-transparent dry lipid thin-film along the inner glass walls of the flask. The film is kept under a vacuum overnight to remove any toxic traces of remaining solvent.

Step 3: Aqueous Hydration and Self-Assembly

The dry lipid thin-film is hydrated by adding an exact volume of Phosphate Buffered Saline (PBS, pH 7.4). The flask is rotated or agitated at a temperature above the lipid $T_c$ . Upon exposure to the water-dense phase, the tail-to-tail hydrophobic forces prompt the lipid film to lift off the glass surface and spontaneously twist into closed, spherical, multi-lamellar vesicles (MLVs), trapping the aqueous hydration medium and dissolved drug within their cores.

Step 4: Particle Dimension Refining (Size Reduction)

To convert the coarse multi-lamellar vesicles into uniform, small, single-layered structures, the crude suspension is subjected to probe sonication or micro-fluidic extrusion workflows. This step refines the physical diameter to a uniform nanometric scale ( \le 150\ { nm} ).

**3.4 Evaluation and Characterization Parameters**

1. Entrapment Efficiency (EE%) Determination

The prepared liposomal suspensions are centrifuged using a High-Speed Refrigerated Centrifuge to separate the encapsulated drug from the unencapsulated free drug. The clear supernatant liquid containing the free drug is analysed via an ultraviolet-visible (UV-Vis) spectrophotometer. The Encapsulation Efficiency is calculated using the following formula:

$$\ {EE}\% = \left( \frac{\ {Total Drug Added} - \ {Free Unencapsulated Drug}}{\ {Total Drug Added}} \right) \times 100$$

2. Particle Size and Polydispersity Index (PDI) Measurement

The average physical diameter and particle size distribution (PDI) of batches $F_1$ to $F_6$ are determined using Dynamic Light Scattering (DLS) at 25^\circ\ . This test monitors how varying the lipid-to-cholesterol ratios structurally impacts the average vesicle diameter and identifies if any clumping or aggregation is occurring.

3. Surface Charge (Zeta Potential) Analysis

The electrostatic surface charge of the vesicles is verified by assessing their Zeta Potential. A high positive or negative millivolt ( \ {mV} ) reading confirms strong electrostatic repulsion between the vesicles, ensuring the suspension remains physically stable during storage without forming large clumps.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

| Category | Specific Example(s) | Function in Assembly |
|---|---|---|
| Primary Lipid | PC (Phosphatidylcholine), DPPC, DSPC | Forms the structural backbone (bilayer). |
| Sterols | Cholesterol | Modulates membrane rigidity and permeability |
| Charged Lipids | Stearyl amine (+), Diacetyl phosphate (-) | Provides surface charge to prevent vesicle aggregation. |
| Hydration Medium | PBS (Phosphate Buffered Saline), Normal Saline | Forms the aqueous core and determines internal pH. |
| Organic Solvent | Chloroform, Methanol, Ethanol | Dissolves lipids to ensure a homogenous molecular mix. |
| Cryoprotectants | Sucrose, Trehalose, Mannitol | Protects vesicles during freeze- drying (lyophilization). |
| Polymer Coating | PEG (Polyethylene Glycol) | Creates a "stealth" layer to avoid immune |

Phospholipids are amphiphilic, meaning they have a water-loving (hydrophilic) head and a water-fearing (hydrophobic) tail.

• Mechanism: When placed in water, these molecules spontaneously align "tail-to-tail" to hide the hydrophobic parts from water, creating the bilayer.

• Choice of Lipid: The length and saturation of the hydrocarbon tails determine the Phase Transition Temperature.

• DPPC making it rigid at body temperature.

• Egg-PC making the liposome "leaky" and fluid.

2. Cholesterol (The Fluidity Buffer)

• Cholesterol does not form bilayers on its own, but it is the "mortar" between the phospholipid "bricks."

• Role: It inserts itself into the spaces created by the phospholipid tails.

• Effect: In fluid membranes, it decreases permeability and increases mechanical stiffness. In rigid membranes, it prevents the tails from packing too tightly, preventing the liposome from becoming brittle. It is essential for preventing the liposome from falling apart when it hits the high-pressure environment of the bloodstream.

3. Charged Lipids (The Electrostatic Guard)

Purely neutral liposomes tend to clump together (aggregate) over time due to Van der Waals forces.

• Positive Charge: Using Stearyl amine can help the liposome bind to negatively charged cell membranes (essential for DNA/RNA delivery).

• Negative Charge: Using Dicetyl phosphate creates Zeta Potential (surface charge). Like magnets with the same pole, these charged liposomes repel

4. Organic Solvents (The Mixing Medium)

• The organic solvent (usually a Chloroform/Methanol mix) is the "temporary stage" for assembly.

• Purpose: Lipids are solids at room temperature. To ensure that the Cholesterol, Phospholipids, and the drug are perfectly mixed at a molecular level, they must be dissolved together.

• Critical Step: The solvent must be completely removed via rotary evaporation. Even trace amounts of Chloroform are toxic and can destabilize the final membrane.

5. Polymer Coating / PEGylation (The Stealth Shield)

This is the most significant "evolutionary" material.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

• The Problem: The body's immune system (macrophages) quickly identifies foreign liposomes and clears them through the liver and spleen.
• The Solution: Attaching Polyethylene Glycol (PEG) to the surface creates a "hydrated cloud" around the liposome. This hides the liposome from the immune system, increasing its "circulation time" from minutes to several hours or days.

6. Cryoprotectants (The Storage Solution)
Because liposomes are mostly water, freezing them causes ice crystals to form, which puncture the delicate lipid bilayers and leak the drug.
• Function: Sugars like Trehalose or Sucrose act as "vitrifying agents." They replace the water molecules around the lipid heads during freeze-drying, maintaining the spacing and preventing the vesicle from collapsing.

Formulation Table :-

| Formula tion Code | Phospholip id (mg) | Cholesterol (mg) | Molar Ratio (PL : CHOL) | Targe t Drug Paylo ad (mg) | Intended Physicochemical / Evaluation Goal |
|---|---|---|---|---|---|
| F_1 | 100 | 0 | 10 : 0 | 10 | Control Batch: Consists of a pure lipid bilayer matrix; expected to exhibit high membrane fluidity and leakiness. |
| F_2 | 90 | 10 | 9 : 1 | 10 | Low Binder Profile: Introduces a minimal framework of cholesterol; test baseline for initial membrane stabilization. |
| F_3 | 80 | 20 | 4 : 1 | 10 | Intermediate Matrix: Designed to evaluate progressive structural modifications and partial drug retention improvements. |
| F_4 | 70 | 30 | 7 : 3 | 10 | Standard Baseline: Representing the standard optimized ratio for structural stability and balanced vesicle formation. |
| F_5 | 60 | 40 | 6 : 4 | 10 | High Rigidity Profile: Dense cholesterol structural packing; expected to establish prolonged, sustained drug release patterns. |
| F_6 | 50 | 50 | 1 : 1 | 10 | Saturation Limit: Maximum theoretical cholesterol incorporation to evaluate the threshold of bilayer saturation. |

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

**EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM**

To systematically determine the exact impact of changing the phospholipid-to-cholesterol ratio on your liposomal systems, the prepared batches
must undergo a series of standardized physicochemical and biopharmaceutical evaluations.

Entrapment Efficiency

Entrapment efficiency determines the percentage of the drug that has been successfully locked inside the liposome (either in the core or the bilayer) versus the amount that remains free in the surrounding fluid.

Procedure:

The crude liposomal suspension is transferred to a high-speed refrigerated centrifuge and spun at 15,000 rpm for 30–45 minutes. This precipitates the heavy liposomes into a solid pellet at the bottom of the tube, leaving the unencapsulated "free" drug dissolved in the clear supernatant liquid on top.

Analysis: The supernatant is collected, diluted, and analysed using a UV-Visible Spectrophotometer at the drug's specific wavelength ( \lambda_{\max} ).

Mathematical Formula: The \ {EE}\% is calculated using the following equation:

Vesicle size directly governs how long the liposomes circulate in the blood and how effectively they can penetrate targeted tissues without being intercepted by the immune system.

• Procedure: A small aliquot of each liposome batch is diluted with distilled water or an appropriate buffer to prevent multiple scattering effects. The sample is placed into a cuvette and analysed using Dynamic Light Scattering (DLS), also known as Photon Correlation Spectroscopy.

• Parameters Tracked:

o Average Particle Size ( Z -Average): Measures the mean hydrodynamic diameter of the vesicles (ideally targeting a nano-range of 100\ { nm} to
150\ { nm} for optimal clinical performance).

o Polydispersity Index (PDI): A dimensionless number ranging from 0.0 to 1.0 that measures the uniformity of the particles. A PDI below 0.2 indicates a highly homogenous, uniform batch, whereas a PDI above 0.5 indicates an unstable, non-uniform suspension.

Surface Charge (Zeta Potential) Analysis

Zeta potential measures the net electrical charge on the surface of the liposomes. This value acts as a primary predictor of the physical storage stability of your colloidal suspension.

• Procedure: The diluted liposomal sample is introduced into a specialized capillary cell containing electrodes, and its electrophoretic mobility is measured using a Zeta Potential Analyzer.

• Evaluation Criteria: Like charges repel each other. If your liposomes have a strong surface charge— either highly positive (due to lipids like Stearylamine) or highly negative (due to lipids like Dicetyl phosphate)—they will naturally push away from one another. A Zeta Potential value greater than
+30\ { mV} or less than -30\ { mV} provides a strong electrostatic guard. This keeps the suspension stable over time and prevents the liposomes from fusing together into large, useless clumps (aggregation).

1 In Vitro Drug Release and Diffusion Kinetics

This evaluation simulates how the liposomal carrier will release its therapeutic payload when circulating inside the human body.

• Procedure: An exact volume of the liposomal suspension from each batch ( F_1 -F_6 ) is loaded into a separate dialysis bag (with a specific molecular weight cut-off). The bag is tightly sealed and immersed into a dissolution vessel containing Phosphate Buffered Saline (PBS, pH 7.4), which acts as the receptor compartment mimicking blood ph.

• Environmental Constraints: The setup is maintained under continuous magnetic stirring at a regulated physiological body temperature of 37 \pm 0.5^\circ\ .

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

• Sampling: At predetermined time intervals (e.g., 1, 2, 4, 8, 12, and 24 hours), a specific volume of the receptor medium is withdrawn for UV spectrophotometric analysis, and an equal volume of fresh PBS is immediately replaced to maintain sink conditions.

2 Master Evaluation Observation Table

This table consolidates the raw data for all characterization parameters across your six formulation profiles. It serves as your main data ledger to prove how varying the cholesterol level alters the physical dynamics of the vesicles.

3 Expected Critical Evaluation Trends

1. Bilayer Leaking Threshold ( F_1 vs F_4 ): Batch F_1 (0% Cholesterol) will establish high initial fluidity. This exhibits a low encapsulation efficiency and a rapid "burst release" curve in the dissolution study because there is no cholesterol to block the lipid pores.

2. The Optimization Apex ( F_4 ): As cholesterol levels increase toward the 7:3 ratio ( F_4 ), the particle uniformity improves (lower PDI values), and the Entrapment Efficiency peaks. This profile typically produces a highly controlled, sustained release pattern over 24 hours.

3. Bilayer Saturation Disruption ( F_6 ): At a 1:1 ratio ( F_6 ), the extreme concentration of cholesterol rigidifies the vesicle to its maximum limit. This structural crowding frequently kicks out the drug molecules from the bilayer space, leading to an unexpected drop in Entrapment Efficiency.

## V. RESULTS AND DISCUSSION

The liposomal drug delivery system was successfully prepared by using the thin film hydration method. The prepared formulations were evaluated for various parameters such as particle size, entrapment efficiency, in-vitro drug release, and stability studies. The results obtained indicated satisfactory performance of the liposomal formulations.

The prepared liposomes appeared as a homogeneous and milky suspension, indicating successful formation of vesicles. The particle size analysis showed that the liposomes were present within the desired size range, which is important for effective drug delivery and enhanced absorption. Uniform particle size distribution was observed in all formulations.

The entrapment efficiency of the prepared liposomes was found to be satisfactory. The results indicated that a significant amount of drug was successfully encapsulated within the liposomal vesicles. Increase in cholesterol concentration improved the stability and entrapment efficiency of the formulation. High entrapment efficiency indicates better drug loading capacity and improved therapeutic effect.

The in-vitro drug release study demonstrated a controlled and sustained release pattern from the liposomal formulation. Initially, a small amount of drug was released rapidly due to the presence of drug on the surface of liposomes, followed by slow and prolonged drug release from the vesicles. This sustained release behavior helps in maintaining therapeutic drug concentration for a longer duration and reduces the frequency of dosing.

The stability study showed that the formulations remained stable during the storage period with minimal changes in particle size, appearance, and drug content.

Refrigerated conditions were found to be more suitable for storage of liposomal formulations compared to room temperature.

Overall, the results confirmed that the prepared liposomal drug delivery system exhibited good stability, satisfactory entrapment efficiency, and controlled drug release profile. These findings suggest that liposomes are promising carriers for targeted and sustained drug delivery applications.

| Parameter | Result Obtained |
|---|---|
| Appearance | Milky homogeneous suspension |
| | |

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 11, May 2026 Impact Factor: 8.2

| | |
|---|---|
| Particle Size | Uniform and satisfactory |
| Entrapment Efficiency | High entrapment observed |
| Drug Release | Sustained release profile |
| Stability | Stable formulation |

## VI. CONCLUSION

In the present study, liposomal drug delivery system was successfully prepared by using the thin film hydration method. The prepared liposomal formulations were evaluated for various parameters such as particle size, entrapment efficiency, in-vitro drug release, and stability studies.

The evaluation results indicated that the prepared liposomes showed satisfactory particle size distribution, high entrapment efficiency, controlled drug release, and good stability. Liposomal formulation was found to improve the bioavailability and therapeutic efficacy of the drug while reducing side effects and toxicity associated with conventional dosage forms.

The study demonstrated that liposomes are effective carriers for targeted and sustained drug delivery applications. The thin film hydration method was found to be simple, reliable, and suitable for preparation of stable liposomal vesicles.

Overall, the liposomal drug delivery system proved to be a promising approach in modern pharmaceutics for enhancing drug delivery and achieving better therapeutic outcomes. Further research and development can help in improving the efficiency and clinical applications of liposomal formulations in the treatment of various diseases.

## REFERENCES

1. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International journal of nanomedicine. 2012 Dec 30:49-60.
2. Barenholz Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. Journal of liposome research. 2003 Jan 1;13(1):1-8.
3. Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Advanced drug delivery reviews. 1999 Nov 10;40(1-2):75-87.
4. Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. Journal of liposome research. 2012 Sep 1;22(3):177-92.
5. Gonzalez-Rodriguez ML, Barros LB, Palma J, González-Rodríguez PL, Rabasco AM. Application of statistical experimental design to study the formulation variables influencing the coating process of lidocaine liposomes. International journal of pharmaceutics. 2007 Jun 7;337(1-2):336-45.
6. Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. Journal of controlled release. 2009 Oct 1;139(1):73-80.
7. Ait-Oudhia S, Mager DE, Straubinger RM. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics. 2014 Mar 18;6(1):137-74.
8. Maritim S, Boulas P, Lin Y. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes. International journal of pharmaceutics. 2021 Jan 5;592:120051.
9. Chountoulesi M, Naziris N, Pippa N, Demetzos C. The significance of drug-to-lipid ratio to the development of optimized liposomal formulation. Journal of liposome research. 2018 Jul 3;28(3):249-58.
10. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. International Scholarly Research Notices. 2012;2012(1):738432.
11. He H, Yuan D, Wu Y, Cao Y. Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs. Pharmaceutics. 2019 Mar 7;11(3):110.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 11, May 2026
Impact Factor: 8.2

12. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Therapeutic delivery. 2013 Aug 1;4(8):1047-72.
13. Gomez-Hens A, Fernandez-Romero JM. Analytical methods for the control of liposomal delivery systems. TrAC Trends in Analytical Chemistry. 2006 Feb 1;25(2):167-78.
14. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Advanced drug delivery reviews. 2011 Sep 16;63(12):1020-30.
15. Frézard F, Aguiar MM, Ferreira LA, Ramos GS, Santos TT, Borges GS, Vallejos VM, De Morais HL. Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations. Pharmaceutics. 2022 Dec 28;15(1):99.
16. Pande S. Factors affecting response variables with emphasis on drug release and loading for optimization of liposomes. Artificial Cells, Nanomedicine, and Biotechnology. 2024 Dec 31;52(1):334-44.
17. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological reviews. 1999 Dec 1;51(4):691-743.
18. Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. Journal of Controlled Release. 2007 Apr 2;118(2):204-15.
19. Maherani B, Arab-Tehrany E, R. Mozafari M, Gaiani C, Linder M. Liposomes: a review of manufacturing techniques and targeting strategies. Current nanoscience. 2011 Jun 1;7(3):436-52.
20. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clinical cancer research. 2005 Dec 1;11(23):8230-4.